Abstract
Gadolinium-diethylene-triamine-penta-acetic acid (Gd-DTPA/dimeglumine) is a clinically useful paramagnetic contrast agent for magnetic resonance imaging (MRI) (1–4). Due to its favorable pharmacokinetic properties and lack of adverse reactions Gd-DTPA proved to be safe for use in humans. When subtle or no differences in signal intensity between normal and pathological tissue exist, Gd-DTPA can enhance contrast between abnormal and normal tissue, thereby increasing sensitivity and specificity of the study. Gd-DTPA produces local alterations in the magnetic environment that enhance MR-relaxation of protons. Unlike conventional radiographic contrast agents that are directly visualized, Gd-DTPA is imaged indirectly by enhancement of proton relaxation due to the seven unpaired electrons of the Gd-ion, which determine the paramagnetic strength.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.